In distilled water with 0.5% acetic acid, reserpine was dissolved, while semaglutide was dissolved in saline
Studies have shown that individuals who achieve and maintain significant weight loss experience fewer gout attacks in the long term compared to before weight reduction, despite potential short-term increases in risk during the active weight loss phase
Etiology * Autoimmune destruction of pancreatic -cells * Genetic predisposition (HLA-DR3, HLA-DR4) * Environmental triggers (e.g., viral infections) Risk Factors * Family history of T1DM * Other autoimmune diseases * Genetic susceptibility * Younger age (peak onset: 47 years and 1014 years) Pathophysiology * Autoimmune -cell destruction * Progressive loss of insulin secretion * Increased hepatic glucose production * Reduced peripheral glucose uptake * Increased lipolysis and ketogenesis * Risk of Diabetic ketoacidosis (DKA) Clinical Features * Polyuria * Polydipsia * Polyphagia * Weight loss * Fatigue * Blurred vision * Nocturia * Recurrent infections * DKA may be the initial presentation Diagnosis Diagnosis is made by any one of the following: * Fasting plasma glucose 126 mg/dL (7.0 mmol/L) * Random plasma glucose 200 mg/dL (11.1 mmol/L) with classic symptoms * 2-hour plasma glucose 200 mg/dL (11.1 mmol/L) during a 75-g oral glucose tolerance test * HbA1c 6.5% (48 mmol/mol) Investigations * Blood glucose * HbA1c * Urinalysis (glucose and ketones) * Serum ketones * Electrolytes and renal function * Arterial or venous blood gas if DKA is suspected * Lipid profile * Thyroid function tests * Screening for Celiac disease and autoimmune thyroid disease Management Insulin Therapy * Lifelong insulin replacement * Basal-bolus regimen (preferred) * Continuous subcutaneous insulin infusion (insulin pump) in selected patients Monitoring * Self-monitoring of blood glucose or continuous glucose monitoring (CGM) * HbA1c every 3 months until stable, then every 36 months Lifestyle * Medical nutrition therapy * Regular physical activity * Carbohydrate counting * Diabetes education * Foot care Hypoglycemia Management * Conscious patient: 1520 g fast-acting carbohydrate * Unconscious patient: IV dextrose or IM glucagon Acute Complications * Diabetic ketoacidosis * Hypoglycemia Chronic Complications Microvascular * Diabetic retinopathy * Diabetic nephropathy * Diabetic neuropathy Macrovascular * Coronary artery disease * Stroke * Peripheral arterial disease Prognosis * Good glycemic control significantly reduces the risk of microvascular complications
It is possible that in the early stages of alcohol drinking ghrelin levels may be reduced and GHS-R1a expression may be increased
both antibiotic use and germ-free conditions suppress the expression of CYP7A1 and CYP27A1, key enzymes involved in BA production based on animal mechanistic studies (Chiang and Ferrell, 2019)
